Interplay Between TGF-β Signaling and MicroRNA in Diabetic Cardiomyopathy

Overview

Journal Cardiovasc Drugs Ther

Specialties Cardiology & Vascular Diseases
Pharmacology

Date 2023 Dec 20

PMID 38117422

Authors

Jianning Qin

Yao Tan

Yang Han

Letian Yu

Shali Liu

Simin Zhao

Hengquan Wan

Shunlin Qu

Affiliations

Soon will be listed here.

Abstract

In diabetic patients, concomitant cardiovascular disease is the main factor contributing to their morbidity and mortality. Diabetic cardiomyopathy (DCM) is a form of cardiovascular disease associated with diabetes that can result in heart failure. Transforming growth factor-β (TGF-β) isoforms play a crucial role in heart remodeling and repair and are elevated and activated in myocardial disorders. Alterations in certain microRNAs (miRNA) are closely related to diabetic cardiomyopathy. One or more miRNA molecules target the majority of TGF-β pathway components, and TGF-β directly or via SMADs controls miRNA synthesis. Based on these interactions, this review discusses potential cross-talk between TGF-β signaling and miRNA in DCM in order to investigate the creation of potential therapeutic targets.

Citing Articles

Diabetic Cardiomyopathy: Role of Cell Death, Exosomes, Fibrosis and Epicardial Adipose Tissue.

Galeone A, Annicchiarico A, Buccoliero C, Barile B, Luciani G, Onorati F Int J Mol Sci. 2024; 25(17).

PMID: 39273428 PMC: 11395197. DOI: 10.3390/ijms25179481.

The signaling pathways of selected traditional Chinese medicine prescriptions and their metabolites in the treatment of diabetic cardiomyopathy: a review.

Li W, Liu X, Liu Z, Xing Q, Liu R, Wu Q Front Pharmacol. 2024; 15:1416403.

PMID: 39021834 PMC: 11251973. DOI: 10.3389/fphar.2024.1416403.

References

Dillmann W . Diabetic Cardiomyopathy. Circ Res. 2019; 124(8):1160-1162. PMC: 6578576. DOI: 10.1161/CIRCRESAHA.118.314665. View

Murtaza G, Virk H, Khalid M, Lavie C, Ventura H, Mukherjee D . Diabetic cardiomyopathy - A comprehensive updated review. Prog Cardiovasc Dis. 2019; 62(4):315-326. DOI: 10.1016/j.pcad.2019.03.003. View

Jia G, Whaley-Connell A, Sowers J . Diabetic cardiomyopathy: a hyperglycaemia- and insulin-resistance-induced heart disease. Diabetologia. 2017; 61(1):21-28. PMC: 5720913. DOI: 10.1007/s00125-017-4390-4. View

Meng X, Nikolic-Paterson D, Lan H . TGF-β: the master regulator of fibrosis. Nat Rev Nephrol. 2016; 12(6):325-38. DOI: 10.1038/nrneph.2016.48. View

Suematsu Y, Miura S, Goto M, Matsuo Y, Arimura T, Kuwano T . LCZ696, an angiotensin receptor-neprilysin inhibitor, improves cardiac function with the attenuation of fibrosis in heart failure with reduced ejection fraction in streptozotocin-induced diabetic mice. Eur J Heart Fail. 2016; 18(4):386-93. DOI: 10.1002/ejhf.474. View

Orom U, Nielsen F, Lund A . MicroRNA-10a binds the 5'UTR of ribosomal protein mRNAs and enhances their translation. Mol Cell. 2008; 30(4):460-71. DOI: 10.1016/j.molcel.2008.05.001. View

Che H, Wang Y, Li Y, Lv J, Li H, Liu Y . Inhibition of microRNA-150-5p alleviates cardiac inflammation and fibrosis via targeting Smad7 in high glucose-treated cardiac fibroblasts. J Cell Physiol. 2019; 235(11):7769-7779. DOI: 10.1002/jcp.29386. View

Zhang Y, Huang X, Wei L, Chung A, Yu C, Lan H . miR-29b as a therapeutic agent for angiotensin II-induced cardiac fibrosis by targeting TGF-β/Smad3 signaling. Mol Ther. 2014; 22(5):974-85. PMC: 4015231. DOI: 10.1038/mt.2014.25. View

Avagimyan A, Popov S, Shalnova S . The Pathophysiological Basis of Diabetic Cardiomyopathy Development. Curr Probl Cardiol. 2022; 47(9):101156. DOI: 10.1016/j.cpcardiol.2022.101156. View

10.

Dewanjee S, Vallamkondu J, Kalra R, John A, Reddy P, Kandimalla R . Autophagy in the diabetic heart: A potential pharmacotherapeutic target in diabetic cardiomyopathy. Ageing Res Rev. 2021; 68:101338. DOI: 10.1016/j.arr.2021.101338. View

11.

Eguchi K, Boden-Albala B, Jin Z, Rundek T, Sacco R, Homma S . Association between diabetes mellitus and left ventricular hypertrophy in a multiethnic population. Am J Cardiol. 2008; 101(12):1787-91. PMC: 2486269. DOI: 10.1016/j.amjcard.2008.02.082. View

12.

Huynh K, Bernardo B, McMullen J, Ritchie R . Diabetic cardiomyopathy: mechanisms and new treatment strategies targeting antioxidant signaling pathways. Pharmacol Ther. 2014; 142(3):375-415. DOI: 10.1016/j.pharmthera.2014.01.003. View

13.

Harmancey R, Lam T, Lubrano G, Guthrie P, Vela D, Taegtmeyer H . Insulin resistance improves metabolic and contractile efficiency in stressed rat heart. FASEB J. 2012; 26(8):3118-26. PMC: 3405268. DOI: 10.1096/fj.12-208991. View

14.

Anderson E, Rodriguez E, Anderson C, Thayne K, Chitwood W, Kypson A . Increased propensity for cell death in diabetic human heart is mediated by mitochondrial-dependent pathways. Am J Physiol Heart Circ Physiol. 2010; 300(1):H118-24. PMC: 3023249. DOI: 10.1152/ajpheart.00932.2010. View

15.

Huang K, Wen S, Huang J, Wang F, Pang L, Wang Y . Integrated Analysis of Hub Genes and miRNAs in Dilated Cardiomyopathy. Biomed Res Int. 2020; 2020:8925420. PMC: 7512046. DOI: 10.1155/2020/8925420. View

16.

Krol J, Loedige I, Filipowicz W . The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet. 2010; 11(9):597-610. DOI: 10.1038/nrg2843. View

17.

Ahmed U, Khaliq S, Ahmad H, Ahmad I, Ashfaq U, Qasim M . Pathogenesis of Diabetic Cardiomyopathy and Role of miRNA. Crit Rev Eukaryot Gene Expr. 2021; 31(1):79-92. DOI: 10.1615/CritRevEukaryotGeneExpr.2021037533. View

18.

Shen E, Diao X, Wang X, Chen R, Hu B . MicroRNAs involved in the mitogen-activated protein kinase cascades pathway during glucose-induced cardiomyocyte hypertrophy. Am J Pathol. 2011; 179(2):639-50. PMC: 3157194. DOI: 10.1016/j.ajpath.2011.04.034. View

19.

Raut S, Kumar A, Singh G, Nahar U, Sharma V, Mittal A . miR-30c Mediates Upregulation of Cdc42 and Pak1 in Diabetic Cardiomyopathy. Cardiovasc Ther. 2015; 33(3):89-97. DOI: 10.1111/1755-5922.12113. View

20.

Kuwabara Y, Horie T, Baba O, Watanabe S, Nishiga M, Usami S . MicroRNA-451 exacerbates lipotoxicity in cardiac myocytes and high-fat diet-induced cardiac hypertrophy in mice through suppression of the LKB1/AMPK pathway. Circ Res. 2014; 116(2):279-88. DOI: 10.1161/CIRCRESAHA.116.304707. View